CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $49.13 in the latest trading session, marking a +0.99% move from the prior day. This change lagged the S&P 500's 1.96% gain on the day. Meanwhile, the Dow gained 1.57%, and the Nasdaq, a tech-heavy index, lost 3.03%.
Heading into today, shares of the company had gained 7.68% over the past month, outpacing the Medical sector's gain of 2.79% and the S&P 500's gain of 2.19% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.67 per share, which would represent year-over-year growth of 28.02%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $37.61 million, up 3901.49% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$7.22 per share and revenue of $155.02 million. These results would represent year-over-year changes of +13.64% and +12839.84%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.73% higher. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
